JP2024542950A5 - - Google Patents
Info
- Publication number
- JP2024542950A5 JP2024542950A5 JP2024523457A JP2024523457A JP2024542950A5 JP 2024542950 A5 JP2024542950 A5 JP 2024542950A5 JP 2024523457 A JP2024523457 A JP 2024523457A JP 2024523457 A JP2024523457 A JP 2024523457A JP 2024542950 A5 JP2024542950 A5 JP 2024542950A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256827P | 2021-10-18 | 2021-10-18 | |
| US63/256,827 | 2021-10-18 | ||
| PCT/US2022/078327 WO2023069967A2 (en) | 2021-10-18 | 2022-10-18 | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542950A JP2024542950A (ja) | 2024-11-19 |
| JPWO2023069967A5 JPWO2023069967A5 (https=) | 2025-10-20 |
| JP2024542950A5 true JP2024542950A5 (https=) | 2025-10-20 |
Family
ID=86058644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523457A Pending JP2024542950A (ja) | 2021-10-18 | 2022-10-18 | Ｃｄｋｌ５欠損症（ｃｄｄ）の治療において有用な組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240425882A1 (https=) |
| EP (1) | EP4419690A4 (https=) |
| JP (1) | JP2024542950A (https=) |
| KR (1) | KR20240100490A (https=) |
| CN (1) | CN118401667A (https=) |
| AU (1) | AU2022369293A1 (https=) |
| CA (1) | CA3235593A1 (https=) |
| CO (1) | CO2024006328A2 (https=) |
| IL (1) | IL312241A (https=) |
| MX (1) | MX2024004723A (https=) |
| WO (1) | WO2023069967A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297635A (en) * | 2020-04-27 | 2022-12-01 | Univ Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2610100B (en) * | 2017-10-23 | 2023-08-16 | Stoke Therapeutics Inc | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases |
| WO2020132455A1 (en) * | 2018-12-21 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| CA3133889A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| WO2021081217A1 (en) * | 2019-10-23 | 2021-04-29 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| CA3156506A1 (en) * | 2019-10-30 | 2021-05-06 | Amicus Therapeutics, Inc. | Recombinant cdkl5 proteins, gene therapy and production methods |
| IL297635A (en) * | 2020-04-27 | 2022-12-01 | Univ Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
-
2022
- 2022-10-18 AU AU2022369293A patent/AU2022369293A1/en active Pending
- 2022-10-18 US US18/702,258 patent/US20240425882A1/en active Pending
- 2022-10-18 EP EP22884659.8A patent/EP4419690A4/en active Pending
- 2022-10-18 JP JP2024523457A patent/JP2024542950A/ja active Pending
- 2022-10-18 WO PCT/US2022/078327 patent/WO2023069967A2/en not_active Ceased
- 2022-10-18 CA CA3235593A patent/CA3235593A1/en active Pending
- 2022-10-18 CN CN202280083857.7A patent/CN118401667A/zh active Pending
- 2022-10-18 KR KR1020247014950A patent/KR20240100490A/ko active Pending
- 2022-10-18 IL IL312241A patent/IL312241A/en unknown
- 2022-10-18 MX MX2024004723A patent/MX2024004723A/es unknown
-
2024
- 2024-05-17 CO CONC2024/0006328A patent/CO2024006328A2/es unknown